Updates in antiplatelet agents used in cardiovascular diseases

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 18, Issue 6, 2013, Pages 514-524

  Cheng, Judy W M ^a  

^a Department of Pharmacy Practice ^*  (China)

Author keywords

acute coronary syndrome; antiplatelet agents; prasugrel; ticagrelor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATOPAXAR; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1 INHIBITOR; PROTON PUMP INHIBITOR; THROMBIN RECEPTOR ANTAGONIST; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; VORAPAXAR;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ARTICLE; BLEEDING; BRADYCARDIA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHEMOPROPHYLAXIS; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG FUNCTION TEST; NEUTROPENIA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OPTIMAL DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REPEATED DRUG DOSE; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ANTIPLATELET AGENTS; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC;

EID: 84887570130     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413499971     Document Type: Article

References (73)

1. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007 ; 357 (24). 2482-2494
2. Go AS, Mozaffarian D, Roger V, et al. Heart disease and stroke statistics - 2013 update: a report from the American heart association. Circulation. 2013 ; 127 (1). 143-152
3. ACCF/AHA Focused Update Incorporated Into the ACC/AHA2007Guidelines for the Management of Patients With Unstable Angina/Non-ST Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart association Task Force on Practice Guidelines; 2013. http://circ. ahajournals.org/content/127/23/e663.full.pdf+html. Accessed July 2, 2013.
4. O'Gara PT, Kushner FG. Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST elevation myocardial infarction. Circulation. 2013 ; 127 (4). e362 - e425
5. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 ; 345 (7). 494-502
6. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001 ; 358 (9281). 527-533
7. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 ; 352 (12). 1179-1189
8. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo controlled trial. Lancet. 2005 ; 366 (9497). 1607-1621
9. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence based clinical practice guidelines. Chest. 2012 ; 141 (2 suppl). e89S - e119S
10. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984 ; 311 (19). 1206-1211
11. Hennekens CH. Aspirin in the treatment and prevention of cardiovascular disease: current perspective and future directions. Curr Atheroscler Rep. 2007 ; 9 (5). 409-416
12. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009 ; 373 (9678). 1849-1860
13. Berger JA, Lala A, Jrantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trial. Am Heart J. 2011 ; 162 (1). 115-124
14. Seshaspirini SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and non-vascular outcomes. meta-analysis of randomized controlled trials. Arch Intern Med. 2012 ; 172 (3). 209-216
15. Sussman JB, Vijan S, Choi H, et al. Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines. Cir Cardiovasc Qual Outcomes. 2011 ; 4 (3). 268-275
16. Shiotani A, Manabe N, Kamada T, Fujimura Y. Risk and prevention factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review. J Gastroenterol Hepatol. 2012 ; 27 (suppl 3). 8-12
17. Nicolucci A, De Berardis G, Sacco M, Tognoni G., AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J. 2007 ; 28 (16). 1925-1927
18. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American heart association science advisory and coordinating committee. Circulation. 2002 ; 106 (3). 388-391
19. Aspirin for the prevention of cardiovascular disease: U.S. preventive services task force recommendation statement. Ann Intern Med. 2009 ; 150 (6). 396-404
20. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American diabetes association, a scientific statement of the American heart association, and an expert consensus document of the American college of cardiology foundation. Diabetes Care. 2010 ; 33 (6). 1395-1402
21. Pignone M, Williams CD. Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat Rev Endocrinol. 2010 ; 6 (11). 619-628
22. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994 ; 90 (4). 1757-1764
23. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation. 1998 ; 97 (17). 1680-1688
24. Montalescot G, Antoniucci D, Kastrati A. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J. 2007 ; 28 (4). 443-449
25. Vickers S, Theoharides AD, Arison B, et al. vitro and in vivo studies on the metabolism of tirofiban Drug Metab Dispos. 1999 ; 27 (11). 1360-1366
26. Madan M, Berkowitz SD. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. Am Heart J. 1999 ; 138 (4 pt 2). 317-326
27. Valgimigli M, Biondi-Zoccai G, Tebaldi M, et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 ; 31 (1). 35-49
28. Smith BS, Gandhi PJ. Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure. J Thromb Thrombolysis. 2001 ; 11 (1). 39-48
29. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimize platelet aggregation and coronary thrombosis-II. Lancet. 1997 ; 349 (9063). 1422-1428
30. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet. 2000 ; 356 (9247). 2037-2044
31. Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009 ; 360 (21). 2176-2190
32. Müller TH, Su CA, Weisenberger H, Brickl R, Nehmiz G, Eisert WG. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol. 1990 ; 30 (2). 179-186
33. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005 ; 31 (2). 174-183
34. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000 ; 84 (5). 891-896
35. Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999 ; 25 (suppl 2). 15-19
36. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005 ; 111 (20). 2560-2564
37. von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect) trial. Circulation.. 2005 ; 112 (19). 2946-2950
38. Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomesin patients with non-ST-segment elevation acute coronary syndromeundergoing coronary stenting. J Am Coll Cardiol.. 2006 ; 48 (7). 1339-1345
39. Montalescot G, Sideris G, Meuleman C, et al.. ALBION Trial Investigators. A randomized comparison of high clopidogrel Cheng 9 loading doses in patients with non-ST-segment elevation acutecoronary syndromes: the ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial. J Am Coll Cardiol... 2006 ; 48 (5). 931-938
40. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007 ; 35 (7). 1096-1104
41. Armstrong PC, Dhanji AR, Tucker AT, Mitchell JA, Warner TD. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost. 2010 ; 8 (3). 613-615
42. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin treated patients with stable coronary artery disease. Eur Heart J. 2006 ; 27 (10). 1166-1173
43. Farid NA, Payne CD, Ernest CS II, et al. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol. 2008 ; 48 (1). 53-59
44. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007 ; 153 (1). e9 - e16
45. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 ; 357 (20). 2001-2015
46. Capodanno D, Dharmashankar K, Angiolillo DJ. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther. 2010 ; 8 (2). 151-158
47. Herbert JM, Frehel D, Vallee E, et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev. 1993 ; 11 (2). 180-198
48. Storey RF. Pharmacology and clinical trials of reversibly binding P2Y12 inhibitors. Thromb Haemost. 2011 ; 105 (suppl 1). S75 - S81
49. Brilinta™ prescribing information; 2012. http://www1.astrazeneca- us.com/pi/brilinta.pdf. Accessed January 5, 2012.
50. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010 ; 38 (9). 1514-1521
51. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 ; 357 (20). 2001-2015
52. Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomized trial. Lancet. 2008 ; 371 (9621). 1353-1363
53. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation. 2008 ; 118 (16). 1626-1636
54. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomized controlled trial. Lancet. 2009 ; 373 (9665). 723-731
55. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009 ; 119 (19). 2553-2560
56. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012 ; 367 (14). 1297-1309
57. Wallentin L, Richard BC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 ; 361 (11). 1045-1057
58. Storey RF, Becker RC, Harrington RA, et al. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the platelet inhibition and platelet outcome (PLATO) pulmonary function substudy). Am J Cardiol. 2011 ; 108 (11). 1542-1546
59. Scirica BM, Cannon CP, Emanuelsson H, et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in PLATO (platelet inhibition and patient outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011 ; 57 (19). 1908-1916
60. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study. Lancet. 2010 ; 375 (9711). 283-293
61. James SK, Row MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized platelet inhibition and patient outcomes (PLATO) trial. BMJ. 2011 ; 342: d3527
62. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (platelet inhibition and patient outcomes) trial. J Am Coll Cardiol. 2011 ; 57 (6). 672-684
63. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation. 2010 ; 122 (21). 2131-2141
64. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2010 ; 122 (11). 1056-1067
65. James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the platelet inhibition and patient outcomes (PLATO) trial. Eur Heart J. 2010 ; 31 (24). 3006-3016
66. Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther. 2009 ; 7 (10). 1195-1201
67. van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost. 2005 ; 31 (2). 195-204
68. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009 ; 361 (24). 2330-2341
69. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013 ; 368 (14). 1303-1313
70. Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Hear J. 2010 ; 31 (1). 17-28
71. Chackalamannil S, Xia Y, Greenlee WJ, et al. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem. 2005 ; 48 (19). 5884-5887
72. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012 ; 366 (1). 20-33
73. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012 ; 366 (15). 1404-1413